The HER family, especially HER2, is considered a therapeutic target in lung cancer because it is overexpressed or mutated in multiple tumors, including lung cancer, and the activation of related pathways, such as MAPK, PI3K, AKT and PKC, can lead to excessive cell proliferation [227], resulting in tumor occurrence and development. Here, PRRT2 is linked to lung carcinoma.